The study is done in two parts. In the first part, different doses of REGN10597 are tested alone and with cemiplimab to see how people tolerate the treatment. In the second part, more people receive the study treatment to learn more about its effect on the cancer. Participants are followed over time while the medicines are given and after treatment ends.

Participants will receive different combinations of medications. One group will receive pembrolizumab and belzutifan, while others may also receive lenvatinib. These drugs are administered through different methods: pembrolizumab is given as an intravenous infusion, which is a liquid medicine delivered directly into a vein, while belzutifan and lenvatinib are taken as pills or capsules by mouth. Some participants may receive a placebo instead of one of the active medications to allow for a comparison between the different treatment groups.

During the study, the effectiveness of the treatment is monitored using a computed tomography scan, commonly known as a CT scan, which uses special X-rays to create detailed pictures of the inside of the body. These scans help to determine if the tumor has decreased in size. The study also tracks how participants feel and any side effects that may occur during the course of the medication.

Participants may receive PF-08634404 through an intravenous method, which involves delivering the medicine directly into a vein. Depending on the assigned group, the treatment may also include ipilimumab, given by intravenous use, or axitinib, which is taken as an oral medication by mouth. The study involves testing these different combinations to see how well they work against the cancer and to identify the best amount of medicine to use.

The purpose of the study is to compare how long people live without their cancer getting worse when they take casdatifan with cabozantinib compared to when they take placebo with cabozantinib. During the study, patients will take their assigned treatment for up to 120 months. The study will check how well the treatment works by using imaging scans to see if the tumors have grown, shrunk, or stayed the same size. These scans will be reviewed by independent experts who are not directly involved in treating the patients.

The study will also look at other important outcomes, including how long people live overall, how many people see their tumors shrink, how long the tumor response lasts, and how many people have their disease stay under control for at least 16 weeks. The study team will carefully monitor any side effects that occur and will track changes in symptoms related to the kidney cancer using questionnaires that ask about disease-related symptoms. Treatment can continue for up to 10 years, and the study is expected to be completed by mid-2029.

The treatment involves receiving intravenous infusions of Lutetium-PSMA-617 (also known as Pluvicto). The medication is given through a vein, and patients may receive up to six treatments over a period of 36 weeks. Each treatment session delivers a carefully measured dose of the radioactive medication that attaches to specific proteins found on cancer cells.

The purpose of this study is to determine how well Lutetium-PSMA-617 works in treating advanced kidney cancer that has not responded well to other treatments. During the study, doctors will monitor how the cancer responds to the treatment through regular imaging scans. The treatment’s safety will also be carefully monitored throughout the study period to track any side effects that patients may experience.

The study is divided into two phases. The first phase will focus on finding the right dose of the medications and checking their safety. The second phase will look at how effective the treatment is in fighting the cancer. The medications are taken by mouth in the form of tablets. Patients will be monitored for any side effects and how their cancer responds to the treatment.

Throughout the study, doctors will track how the tumors respond to treatment, how long the response lasts, and how long patients survive without their cancer getting worse. They will also monitor the overall survival of patients and look for any benefits from the treatment. Regular medical check-ups and tests will be performed to ensure patient safety and evaluate the treatment’s effectiveness.

The purpose of the study is to assess how well Raludotatug Deruxtecan works in treating these cancers and to monitor any side effects. Participants in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will follow participants over a period to observe the treatment’s impact on their cancer and overall health.

Throughout the trial, researchers will focus on understanding how the treatment affects the size and growth of the tumors, as well as any changes in the participants’ health. The study aims to provide valuable information on the potential benefits and risks of using Raludotatug Deruxtecan for these types of cancers, contributing to future treatment options for patients with advanced or metastatic solid tumors.

The study will follow patients over a period to see how they respond to the treatment, including any changes in their cancer and their overall health. It will also look at how well patients tolerate the medications, any side effects they experience, and how the treatment affects their quality of life. The study aims to gather information on the starting doses of Cabozantinib, any changes in dosage, and any interruptions in treatment due to side effects.

Participants in the study will be monitored for various outcomes, such as how long they live without the cancer getting worse, their overall survival, and their response to the treatment based on medical imaging. The study will also track any unplanned hospital visits and assess the quality of life reported by the patients themselves. This information will help to better understand the use of Cabozantinib and Nivolumab in treating older patients with this type of kidney cancer.

Participants in the study will undergo a PSMA-PET scan early in their treatment process. This scan will be repeated six weeks after starting their cancer treatment, which may include combinations of immune checkpoint inhibitors (ICI) and tyrosine kinase inhibitors (TKI). The study aims to see if changes in the scan results can help predict how well the cancer treatment is working, as measured by the Disease Control Rate (DCR) at six months. The DCR is a measure of how many patients have a complete response, partial response, or stable disease after treatment.

The study will also look at other outcomes, such as the Objective Response Rate (ORR), which includes the number of patients with complete or partial responses, and Progression-Free Survival (PFS), which is the time from the start of treatment until the disease progresses, the patient passes away, or the last follow-up. By understanding these correlations, the study hopes to improve the prediction of treatment success in patients with metastatic clear cell renal carcinoma.

The purpose of the study is to see how well Cabozantinib works in patients who have already received one immunocheckpoint inhibitor. Participants in the study will take Cabozantinib and will be monitored to see how their cancer responds to the treatment. The study will also look at how long patients live without their cancer getting worse, which is known as progression-free survival. Additionally, the study will gather information on the overall survival of patients, the response rates to the treatment, and the safety of the drug.

Throughout the study, patients will have regular check-ups and tests to monitor their health and the effects of the treatment. The study aims to provide valuable information on the effectiveness and safety of Cabozantinib for treating advanced kidney cancer in patients who have already tried other treatments. This research could help improve future treatment options for people with this type of cancer.

The purpose of the study is to find out how well these medications work together in treating high-risk non-metastatic clear cell RCC. Participants in the study will receive different combinations of these medications before they have surgery to remove the cancer. The study will look at how the cancer responds to the treatment and how safe the medications are for the patients. Some participants will receive a placebo, which is a treatment that looks like the real medication but does not contain any active ingredients.

The study will take place over several months, and participants will be closely monitored by the research team. They will have regular check-ups and tests to see how the treatment is affecting their cancer and overall health. The study aims to provide valuable information about the effectiveness of these treatments in preventing the cancer from coming back or spreading. This research could help improve future treatment options for people with clear cell RCC.

The purpose of the study is to evaluate the safety and effectiveness of these treatments. The study is divided into three parts. In the first part, participants will receive a single dose of Debio 0328 to assess its safety and how well it can help in imaging the tumors. In the second part, the study will determine the best dose of Debio 0228 for each type of cancer. The third part will explore the potential of Debio 0228 to reduce the size of the tumors. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatments.

Throughout the study, participants will be closely monitored for any side effects and changes in their health. The study aims to gather information on how the body absorbs and processes these treatments, as well as their impact on the tumors. This research could provide valuable insights into new ways to treat these challenging cancers.

The purpose of the study is to find the best dose of these medications and to see how safe and effective they are when used together. Participants will receive the medications in different combinations, either as a single treatment or in pairs or triplets. The study will also look at how the body processes these medications and how they affect cancer cells. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment.

During the study, participants will receive the treatment over a period of time, and their health will be closely monitored by the research team. The study will help determine the safety and potential benefits of these treatments for people with advanced cancers. The information gathered will contribute to understanding how these medications can be used to treat different types of cancer effectively.

The purpose of the study is to compare two different doses of Belzutifan—120 mg and 200 mg—to determine which dose is more effective. Participants in the study will receive one of these doses daily. The study will monitor how well the cancer responds to the treatment and how long the effects last. It will also track the overall health and survival of the participants, as well as any side effects they may experience.

Throughout the study, participants will be regularly assessed to see how their cancer is responding to the treatment. This will involve various tests and evaluations to ensure the safety and effectiveness of the medication. The study aims to provide valuable information that could lead to new treatment options for people with advanced kidney cancer.

The purpose of the study is to compare how well patients do without the cancer coming back after treatment with Belzutifan plus Pembrolizumab versus those receiving a placebo plus Pembrolizumab. Participants in the study will have undergone surgery to remove the kidney tumor, a procedure known as nephrectomy. The study will follow participants over a period of time to monitor their health and any changes in their condition. The main focus is on how long patients remain free from cancer after treatment, which is referred to as disease-free survival.

Throughout the study, researchers will also look at other important factors, such as overall survival, any side effects experienced by participants, and changes in quality of life. The study aims to provide valuable information on whether the combination of Belzutifan and Pembrolizumab can help prevent the return of renal cell carcinoma after surgery, potentially offering a new treatment option for patients with this type of cancer.